APRIL-potentiated plaque regression via computationally optimized cholesterol sequestration nanotherapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Cancer, Lipids, and Metabolism · Coronary Interventions and Diagnostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (31)
Show source-provided references
1. The immune system in atherosclerosis10.1038/ni.2001 ↗
2. The changing landscape of atherosclerosis10.1038/s41586-021-03392-8 ↗
3. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease10.1161/CIRCRESAHA.115.307611 ↗
4. Exosomes in atherosclerosis: performers, bystanders, biomarkers, and therapeutic targets10.7150/thno.56035 ↗
5. Progress and challenges in translating the biology of atherosclerosis10.1038/nature10146 ↗
6. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
7. Arteriosclerosis, atherosclerosis, and cardiovascular health: joint relations to the incidence of cardiovascular disease10.1161/HYPERTENSIONAHA.121.18075 ↗
8. Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy10.1016/j.jacc.2023.08.019 ↗
9. Molecularly targeted nanomedicine enabled by inorganic nanoparticles for atherosclerosis diagnosis and treatment10.1016/j.addr.2023.114709 ↗
10. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa
11. APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans10.1038/s41586-021-03818-3 ↗
12. Identification of proteoglycans as the APRIL-specific binding partners10.1084/jem.20042309 ↗
13. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation
14. Promoting APRIL interaction to control atherosclerosis10.1038/d41573-021-00152-1 ↗
15. Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues10.1073/pnas.2404309121 ↗
16. a proliferation-inducing ligand (APRIL) in the pathogenesis of immunoglobulin a nephropathy: a review of the evidence10.3390/jcm12216927 ↗
17. Macrophages express membrane bound form of APRIL that can generate immunomodulatory signals10.1111/j.1365-2567.2010.03306.x ↗
18. LDL-cholesterol lowering with obicetrapib10.1038/s41569-025-01173-8 ↗
19. Therapeutic precision gene editing of cholesterol pathways as a gene therapy strategy for cardiovascular disease
20. Pitavastatin and resveratrol bio-nanocomplexes against hyperhomocysteinemia-induced atherosclerosis via blocking ferroptosis-related lipid deposition10.1016/j.jconrel.2025.113598 ↗
21. Nucleic acid therapeutics: past, present, and future10.1016/j.omtn.2024.102440 ↗
22. Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas910.1016/j.nantod.2023.102097 ↗
23. Mussel-inspired chemistry: a promising strategy for natural polysaccharides in biomedical applications10.1016/j.progpolymsci.2021.101472 ↗
24. Clickable polysaccharides for biomedical applications: a comprehensive review10.1016/j.progpolymsci.2022.101590 ↗
25. Affinity-driven design of cargo-switching nanoparticles to leverage a cholesterol-rich microenvironment for atherosclerosis therapy10.1021/acsnano.9b08216 ↗
26. Site-specific MicroRNA-33 antagonism by pH-responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity
27. Rapid removal of organic micropollutants from water by a porous β-cyclodextrin polymer10.1038/nature16185 ↗
28. Engineered self-assembly of amphiphilic cyclodextrin conjugates for drug encapsulation10.1021/acsbiomaterials.2c01023 ↗
29. Polycations and their biomedical applications10.1016/j.progpolymsci.2016.05.004 ↗
30. Reactive oxygen species-responsive small interfering RNA nanotherapeutics for treatment of myocardial fibrosis10.1007/s11431-025-3101-1 ↗
31. Structure and function of the immune system in the spleen10.1126/sciimmunol.aau6085 ↗